corporate_fare

Nsc Therapeutics GmbH

Address
Willersdorfer Strasse 7

Sponsor Overview

assignment
1
sponsored trial
science
2
molecules
location_city
22
research centres
public
4
countries
person_search
21
investigators

Specializations

Alzheimer's disease

Nsc Therapeutics GmbH focuses on clinical research in Alzheimer's disease, with attention to mild to moderate cognitive impairment and symptomatic treatment domains linked to memory, attention, and daily functioning.

  • Muscarinic M1 receptor agonism
  • Cognitive symptoms in Alzheimer's disease
  • Neurodegenerative disorders

The sponsor’s clinical interest includes central nervous system therapies aimed at modulating cholinergic signaling in Alzheimer's disease.

Neurology

The company’s research profile is centered on neurology, particularly conditions involving progressive neurodegeneration and impairment of cognitive performance.

  • Memory loss
  • Behavioral and cognitive decline
  • Central nervous system therapeutics

Its funded trial activity reflects an interest in therapies designed for patients with chronic neurocognitive disease.

Neuropharmacology

Nsc Therapeutics GmbH is engaged in neuropharmacology, with emphasis on agents that act on muscarinic receptors and other pathways relevant to brain function.

  • Cholinergic modulation
  • Selective receptor targeting
  • Symptomatic treatment of dementia

This area aligns with therapeutic development for cognitive disorders where restoring neurotransmitter balance is clinically relevant.

Clinical research in dementia

The sponsor’s active trial portfolio includes investigation of treatments for dementia, especially interventions intended to address the clinical burden of Alzheimer-type neurocognitive decline.

  • Therapies for mild to moderate dementia
  • Symptom management in neurodegenerative disease
  • Exploratory efficacy in cognitive disorders

Research activity is concentrated on treatment options for patients with progressive loss of cognitive and functional abilities.

Sponsored Trials

Trial Name Country Status
Evaluation of Safety, Tolerability, and Explorative Efficacy of NSC001 and Trospium Chloride in Mild to Moderate Alzheimer's DiseaseAustria AustriaCzechia CzechiaGermany GermanyItaly ItalyRecruiting

Data & Insights

science
Molecule Portfolio
Compounds under investigation
1
Exclusive Molecules
out of 2 total (50% not shared with other sponsors)

This sponsor works with 2 molecules, of which 1 is not being studied by other sponsors.

hub
Site Partnerships
Collaboration with research centres
0%
Return partnership rate
0 of 22 sites collaborated multiple times

This sponsor has worked with 22 sites across their trial portfolio.

Therapeutic Focus

  • 1.
    Nervous System Diseases1 trial
    449 other sponsors

Partnered Research Centres

22 centres
location_city
assignment185
Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone
Address
Via Del Vespro 129, 90127 Palermo
Learn morearrow_forward
location_city
assignment112
Azienda Ospedaliero Universitaria Ospedali Riuniti
Address
Viale Luigi Pinto 1, 71122 Foggia
Learn morearrow_forward
location_city
assignment244
Azienda Ospedaliero-Universitaria Maggiore Della Carita
Address
Corso Giuseppe Mazzini 18, 28100 Novara
Learn morearrow_forward
location_city
assignment83
Azienda Sanitaria Universitaria Giuliano Isontina
Address
Strada Di Fiume 447, 34149 Trieste
Learn morearrow_forward
location_city
assignment2
Charles University Hospital
Address
V Uvalu 84/1 Motol, 150 00 Prague
Learn morearrow_forward
location_city
assignment5
Dynamikos GmbH Institut fuer Studien zur Psychischen Gesundheit
Address
Richard-Wagner-Strasse 2, Oststadt, 68165 Mannheim
Learn morearrow_forward
Page 1 of 4

Want to get in touch with this sponsor?

Send a question and we'll pass it on to Nsc Therapeutics GmbH.

Need a custom report on this sponsor?

Competitive positioning, market entry, partnership opportunities — tell us the question.

Is something out of date?

Tell us what needs correcting and we'll update this profile.